28.6 C
Vientiane
Monday, September 22, 2025
spot_img
Home Blog Page 61

Glac Biotech Secures U.S. Food and Drug Administration GRAS Approval for Probiotic Strain CP-9

TAIPEI, Sept. 15, 2025 /PRNewswire/ — Glac Biotech, a Taiwan-based developer of probiotics and postbiotics, announced that its core probiotic strain CP-9 (Bifidobacterium lactis CCTCC M 2014588) has been approved with Generally Recognized as Safe (GRAS) status by the U.S. Food and Drug Administration (FDA).

With this notification, Glac Biotech becomes the only probiotic raw material manufacturer in Taiwan to hold multiple FDA GRAS approval, following the recognition of Lactobacillus rhamnosus MP108 in 2023.

Glac Biotech has now secured FDA GRAS approval for two probiotics for use in a broad array of food and beverage products.
Glac Biotech has now secured FDA GRAS approval for two probiotics for use in a broad array of food and beverage products.

Approval Highlights CP-9’s Safety and Quality

According to the FDA filing, CP-9 is authorized for use at levels up to 10⁹ colony-forming units (CFUs) per-serving in a wide range of food and beverage products:

  • Sports and energy drinks
  • Fortified waters
  • Bottled teas
  • Cereals
  • Dairy and non-dairy items
  • Nutrition bars
  • Candies
  • Fruit juices
  • Soy and plant-based protein products
  • Infant foods

The newly approved CP-9 was a finalist at the 2023 NutraIngredients Awards and has been studied for its role in gut health and immune regulation. With FDA GRAS status, CP-9 expands Glac Biotech’s portfolio and is expected to serve the infant and family nutrition markets alongside established strains such as Bifidobacterium lactis BB-12.

Growing Portfolio of Probiotic and Postbiotic Solutions

Glac Biotech’s first GRAS-notified strain, MP108, was shortlisted for the NutraIngredients Awards in 2021 and approved by the FDA in 2023. It was the first probiotic strain in Asia to be approved for infant use. Supported by clinical and safety data, MP108 is permitted for use at up to 10⁹ CFUs per serving in:

  • Sports and energy drinks
  • Fortified waters
  • Nutritional beverages
  • Bottled teas
  • Processed fruits and juices
  • Cereals
  • Cheeses
  • Yogurts
  • Milk-based desserts
  • Soy-based products
  • Nutrition bars
  • Candies
  • Infant foods

Also advancing in postbiotics, Glac’s flagship product Totipro® is available in Europe, Southeast Asia, and North America, and is planned for FDA GRAS submission in the near future. Totipro® is the only raw material publicly declared to meet all four postbiotic categories defined by the International Probiotics Association (IPA): intact cells (IC), cell fragments and cytoplasmic contents (FC), microbial metabolites (MM), and fermentation media containing microbial components (CX).

“FDA GRAS approval represents an important standard of quality and safety. With CP-9 now approved, MP108 already recognized, and Totipro® submission soon, Glac Biotech is advancing its probiotics and postbiotics research with consistency and international alignment. We will continue to base our work on scientific evidence, cooperating with partners worldwide to develop reliable health solutions,” concluded Shin-Yu Tsai, Product and Marketing Department Manager of Glac Biotech.

For more information, visit glacbiotech.com or follow Glac Biotech on LinkedIn and Facebook.

About Glac Biotech

Founded in 2008, Glac Biotech is a subsidiary of Center Laboratories Inc., Taiwan’s largest liquid pharmaceutical manufacturer. The company focuses exclusively on probiotics (PRONULIFE®) and postbiotics (Totipro®), with over 30 researchers and 30 quality specialists overseeing strain development, patents, clinical validation, and international certification.

Ribbon Names Steve McCaffery Executive Vice President, Global Sales

Brings Global Expertise in Accelerating Revenue Growth

PLANO, Texas, Sept. 15, 2025 /PRNewswire/ — Ribbon Communications Inc. (Nasdaq: RBBN), a global leader in real-time communications technology and IP optical networking solutions, today announced the appointment of Steve McCaffery as Executive Vice President of Global Sales, effective end of October, 2025. McCaffery will be based in the UK and report to CEO Bruce McClelland.

“As a global company operating in a dynamic marketplace, we continue to evolve our organization to ensure we have the strongest team to meet our customers’ evolving demands and to capitalize on emerging trends,” said Bruce McClelland, CEO of Ribbon. “Steve’s extensive relationships and experience leading through significant technological shifts, including the recent surge in data center investment to support wide-spread adoption of AI, will be a tremendous asset as we drive sustainable growth worldwide. I’m thrilled to welcome him back to Ribbon and look forward to his impactful leadership.”

McCaffery will leverage his considerable experience with Service Providers, Enterprise, Government, and Critical Infrastructure operators across many regions of the world in this new role. He brings a strong track record of helping customers navigate emerging technologies, including the opportunity-rich data center space. McCaffery has held senior roles at major corporations including Halo Technology (an Amphenol company), Motorola, Google, ARRIS and others. He previously served as head of APAC and EMEA sales at Ribbon from 2021 to 2023.

“This is an exciting and evolving time for our industry,” McCaffery said. “I look forward to working with Ribbon’s world-class sales organization and leadership team to deliver exceptional value to our customers, and seize growth opportunities worldwide.”

McCaffery succeeds Dan Redington, who will be leaving Ribbon at the end of the month to pursue other opportunities.

About Ribbon
Ribbon Communications (Nasdaq: RBBN) delivers secure cloud communications and IP and optical networking solutions to service providers, enterprises and critical infrastructure sectors globally. We engage deeply with our customers, helping them modernize their networks for improved competitive positioning and business outcomes in today’s smart, always-on and data-hungry world. Our end-to-end portfolio of communications software and IP Optical networking solutions delivers superior value and innovation by leveraging cloud-native architectures, automation and analytics tools, and leading-edge security. We maintain a keen focus on our commitments to Environmental, Social, and Governance (ESG) matters, offering an annual Sustainability Report to our stakeholders. To learn more about Ribbon, please visit rbbn.com

Important Information Regarding Forward-Looking Statements
The information in this release contains forward-looking statements regarding future events that involve risks and uncertainties. All statements other than statements of historical facts contained in this release, including those regarding the expected benefits from use of Ribbon Communication’s products, are forward-looking statements. The actual results of Ribbon Communications may differ materially from those contemplated by the forward-looking statements. For further information regarding risks and uncertainties associated with Ribbon Communications’ business, please refer to the “Risk Factors” section of Ribbon Communications’ most recent annual or quarterly report filed with the SEC. Any forward-looking statements represent Ribbon Communications’ views only as of the date on which such statement is made and should not be relied upon as representing Ribbon Communications’ views as of any subsequent date. While Ribbon Communications may elect to update forward-looking statements at some point, Ribbon Communications specifically disclaims any obligation to do so.

Investor Contact 
+1 (978) 614-8050
ir@rbbn.com

Media Contact
Catherine Berthier
+1 (646) 741-1974
cberthier@rbbn.com 

NYSE Content Advisory: Pre-Market Update + S&P comes off best week since August

NEW YORK, Sept. 15, 2025 /PRNewswire/ — The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today’s NYSE Pre-market update for market insights before trading begins. 

 

NYSE Content Advisory: Pre-Market Update + S&P comes off best week since August

Ashley Mastronardi delivers the pre-market update on September 15th

  • Equities are higher Monday morning after a winning week on Wall Street. The S&P 500 recorded its best week since Early August with a gain of 1.6%. The DOW also snapped a losing streak.
  • Investors will be monitoring the latest with Nvidia after China says the firm violated an anti-monopoly law. This week’s activity will be dominated by the Federal Reserve with the central bank to deliver its next policy decision.
  • The Fed’s decision on interest rates will draw headlines, but investors will be keeping a close eye on other data points as well. The Empire State Manufacturing Index was released ahead of todays open.

Opening Bell
Deutsche Bank (NYSE: DB) celebrates Hispanic Heritage Month

Closing Bell
Union Pacific (NYSE: UNP) celebrates the company’s 155th anniversary of listing

Click here to download the NYSE TV App

 

Video – https://mma.prnasia.com/media2/2772918/NYSE_Market_Update_Sept_15.mp4

 

 

 

HitGen Partner BioAge Labs Initiates Phase 1 Clinical Study of BGE-102, a Novel Brain-Penetrant NLRP3 inhibitor

  • BGE-102, an orally available, brain-penetrant NLRP3 inhibitor, was developed from a hit compound identified using HitGen’s industry-leading DEL technology platform, highlighting the value of DEL to accelerate innovative drug development.
  • The initiation of the BGE-102 Phase 1 clinical study triggers a milestone payment to HitGen.

CHENGDU, China, Sept. 15, 2025 /PRNewswire/ — Shanghai Stock Exchange listed company HitGen Inc. (“HitGen”, SSE: 688222.SH), congratulates its partner BioAge Labs, Inc. (“BioAge”, NASDAQ: BIOA), a clinical-stage biotechnology company based in Emeryville, CA, USA, on the initiation of a Phase 1 clinical study of BGE-102, a novel, potent NLRP3 inhibitor developed from a hit compound identified using HitGen’s industry-leading DEL technology platform. The event triggers an undisclosed milestone payment to HitGen under the collaboration agreement between the two companies.

BGE-102 is a structurally novel, orally available small molecule NLRP3 inhibitor with high potency and brain penetration being developed initially for the treatment of obesity. NLRP3 is a key driver of age-related inflammation that has been implicated in a broad range of diseases, including neurodegenerative conditions and cardiovascular disease as well as metabolic disorders such as obesity. BioAge identified NLRP3 as a therapeutic target for metabolic and age-related diseases and sought to develop novel inhibitors, leading to the successful collaboration with HitGen.

BGE-102 was developed by BioAge from hit compounds identified in a screen using HitGen’s DEL libraries under a collaboration agreement between the parties. In April 2021, the companies announced the successful identification of promising hit molecules. In February 2024, the companies further detailed their research collaboration outcome in a joint publication in Bioorganic & Medicinal Chemistry Letters, entitled “The discovery of novel and potent indazole NLRP3 inhibitors enabled by DNA-encoded library screening”. The collaboration has also resulted in joint patent filings covering the structurally novel compounds discovered through the DEL screening process. BioAge and HitGen continue to collaborate on additional drug lead discovery programs for other novel targets using HitGen’s DEL platform.

Dr. Jin Li, Chairman of the Board and Chief Executive Officer of HitGen Inc., stated: “We extend our congratulations to the BioAge team on this exciting progress. The advancement of BGE-102 into clinical studies not only validates the power of HitGen’s DEL platform to discover novel small molecules against challenging targets, but also reinforces the value of our partnership model. We look forward to continuing our collaboration and following the development of this promising candidate.”

“We’re excited to reach this important clinical milestone with BGE-102,” said Kristen Fortney, PhD, CEO and co-founder of BioAge. “HitGen’s DEL platform helped us identify structurally distinct NLRP3 inhibitors with a novel binding site and strong potency and brain penetration. Our collaboration demonstrates the value of combining HitGen’s cutting-edge screening technology with insights from human aging biology to advance potentially transformative treatments for metabolic diseases.”

HitGen is a world leader in the development of DEL technology and applications to early-stage small molecule drug discovery. Its platform includes over 1.2 trillion small molecules generated by the DEL technology, and the efficiency of the screening process has made it possible for HitGen to enable drug discovery projects for many organizations around the world.

About HitGen Inc.

HitGen Inc. (SSE: 688222.SH), is a drug discovery research company headquartered in Chengdu, China, with subsidiaries in Cambridge, UK and Houston, USA. HitGen has established leading technology platforms to enable the discovery and optimization of small molecules and nucleic acid-based drugs. Our key technology platforms include world-leading DNA-encoded library technology (DEL), fragment-based drug discovery and structure-based drug design technologies (FBDD/SBDD), as well as the emerging technology platforms for oligonucleotide-based therapeutics (OBT), and targeted protein degradation technology (TPD). Meanwhile, we are developing a DEL+AI+Automated DMTA (Design-Make-Test-Analyze) molecular optimization platform to accelerate the discovery and optimization process of preclinical candidate compounds. Through our diverse and flexible business models, we have built up collaboration partnerships with several hundred biopharmaceutical research organizations worldwide. HitGen has multiple programmes from early discovery to clinical trial stage.

About BioAge Labs, Inc.

BioAge (NASDAQ: BIOA) is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The Company’s lead product candidate, BGE-102, is a potent, orally available, brain-penetrant small-molecule NLRP3 inhibitor being developed for obesity. BGE-102 has demonstrated significant weight loss in preclinical models both as monotherapy and in combination with GLP-1 receptor agonists. A Phase 1 SAD/MAD trial of BGE-102 is underway, with initial SAD data anticipated by end of year. The Company is also developing long-acting injectable and oral small molecule APJ agonists for obesity. BioAge’s additional preclinical programs, which leverage insights from the Company’s proprietary discovery platform built on human longevity data, address key pathways involved in metabolic aging.

AMPLIFON: -42% DIRECT EMISSIONS AND -25% INDIRECT GREENHOUSE GAS EMISSIONS BY 2030

MILAN, Sept. 15, 2025 /PRNewswire/ — Amplifon, a global leader in hearing solutions and services, is launching its climate strategy validated by the Science Based Targets Initiative (SBTi) to reduce greenhouse gas emissions and contribute to achieving the goals of the 2015 Paris Agreement to counteract climate change.

The strategy, Listening to our Planet,” specifically calls for a 42% reduction in the company’s direct greenhouse gas emissions (Scope 1 and 2) by 2030 compared to 2023. Over the same period, the company has committed to reducing indirect Scope 3 emissions by 25%, deriving from purchased goods and services, capital goods, fuel and energy related activities, upstream transportation and distribution, employee commuting, upstream leased assets, use of sold products and franchises. The plan also stipulates that, by 2030, 44.36% of its suppliers in terms of emissions related to purchased goods and services will have greenhouse gas emission reduction targets based on climate science.

The launch of a scientifically validated climate strategy,” comments Amplifon CEO Enrico Vita, “represents a further step forward in the process of fully integrating ESG factors into our business. Making concrete commitments to reduce our direct and indirect emissions in the medium term is in line with the sustainability plan we launched last year with 20 concrete and measurable targets for 2026, 2028, and 2030 in the areas of products and services, ethics and environmental responsibility, people, and communities. We want to continue to grow in an increasingly responsible and sustainable manner.”

The Science Based Targets Initiative, a non-profit organization launched in 2015 by a coalition of international actors such as CDP, UN Global Compact, World Resources Institute, WWF, and We Mean Business Coalition, supports companies in setting greenhouse gas emission reduction targets consistent with the latest scientific evidence on climate change.

Amplifon’s Corporate Website 

Amplifon’s Sustainability Plan

New Climate Strategy

Amplifon

Amplifon, hearing care global leader, empowers people to rediscover all the emotions of sound. Amplifon’s over 20,000 people worldwide strive every day to understand the unique needs of every customer, delivering exclusive, innovative and highly personalized products and services, to ensure everyone the very best solution and outstanding experience. The Group, with annual revenues of over 2.4 billion euros, operates through a network of over 10,000 points of sale in 26 Countries and 5 continents.

 

Corporate Communication

Salvatore Ricco

M. 39 335 770 9861

salvatore.ricco@amplifon.com

 

 

LabConnect and OmniScience to Deliver First Agentic AI Solution for Real-Time Clinical Trial Lab Insights

Together we’re unlocking the true potential of clinical trial lab data, bringing faster insights, smarter decisions, and better outcomes.

JOHNSON CITY, Tenn. and HOUSTON, Sept. 15, 2025 /PRNewswire/ — LabConnect, a leading global provider of central laboratory services today announced plans to form a strategic collaboration with OmniScience, the AI company behind Vivo, the first agentic AI control tower for clinical trials. Together, they will deliver the industry’s first AI-driven solution enabling sponsors to gain intelligent, real-time insights from clinical trial lab data.

LabConnect and OmniScience logos
LabConnect and OmniScience logos

Faster Decisions and Smarter Oversight with LabConnect + Vivo 
Clinical trial lab data is often siloed, complex, and delayed. This causes slow decision-making and introduces risk. By combining LabConnect’s expertise in central lab testing and data management with OmniScience’s Vivo platform, trial sponsors can now unify fragmented lab datasets, automate oversight, and surface risk signals that accelerate trial timelines and improve outcomes.

About Vivo: Real-Time Intelligence for Clinical Trials, Purpose-Built for Lab Data
Vivo is an AI-native clinical trial intelligence platform that transforms how teams interact with data across the clinical development lifecycle. Designed to unify disparate sources and deliver real-time insights, Vivo functions as a control tower equipping clinical, operational, safety, and data science teams with the clarity to act faster and more confidently. Vivo-Lab, a specialized implementation of Vivo, brings this same intelligence to laboratory data. Vivo-Lab streamlines lab workflows by surfacing critical trends, anomalies, and site-level discrepancies as they happen, helping teams move from reactive to proactive oversight in one of the most complex and variable data streams in clinical research.

Transforming Lab Data into Real-Time Action
“Our mission at OmniScience is to help trial teams see and act faster,” said Angela Holmes, CEO and Co-Founder of OmniScience. “Partnering with LabConnect extends that vision by transforming lab data into real time actionable intelligence that sponsors can trust.”

Wes Wheeler, CEO of LabConnect, added: “At LabConnect, we’re committed to helping sponsors unlock the full potential of their lab data. By integrating OmniScience’s transformative AI, we are shifting lab results from static reports into dynamic, actionable intelligence. Together, we’re giving clinical operations teams the speed, agility, and precision they need to make smarter decisions, improve trial efficiency, and bring therapies to patients faster.”

The partnership underscores both organizations’ commitment to innovation in clinical development, bringing together LabConnect’s technology-driven laboratory operations and OmniScience’s AI-native approach to trial intelligence.

About LabConnect
LabConnect, LLC is the leading provider of Central Laboratory Services, FSP and Scientific Consulting, and Data Integration and Transformation Services for analytically and logistically complex studies such as immuno-oncology, cell and gene therapies, and rare & orphan diseases.

LabConnect’s unique combination of state-of-the-art technology, world-class laboratories, easy access to major and emerging markets, and extensive specialized testing expertise means that drug development companies can rely on one provider for all their central laboratory service needs.

Learn more at www.labconnect.com and follow on LinkedIn.

About OmniScience
OmniScience is a leading AI company transforming clinical development with Vivo, the first agentic AI control tower purpose-built for clinical trials. Built by a team of PhD-trained clinical data scientists, Vivo unifies fragmented trial data, applies intelligent automation, and delivers real-time, explainable insights that help sponsors reduce costs, shorten timelines, and increase trial success rates. Award winning and recognized by programs including Johnson & Johnson’s JLABS, NVIDIA Inception, and Google Cloud for AI, OmniScience is pioneering a new era of clinical trial intelligence to accelerate the delivery of life-changing treatments to patients.

 

BioCatch Receives Frost & Sullivan’s 2025 Global Competitive Strategy Leadership Recognition for Excellence in Fraud Detection and Prevention

This recognition underscores BioCatch’s strategic focus on fraud detection and prevention for the BFSI industry leveraging behavioral biometrics and customer collaboration

SAN ANTONIO, Sept. 15, 2025 /PRNewswire/ — Frost & Sullivan is pleased to announce that BioCatch, which prevents financial crime by recognizing patterns in human behavior, has earned the 2025 Global Competitive Strategy Leadership Recognition in the BFSI fraud detection and prevention (FDP) industry for its outstanding achievements in strategy execution, innovation, and customer impact. This recognition highlights BioCatch’s consistent leadership in combating fraud, strengthening its market position, and delivering customer-centric innovation in an evolving threat landscape.

Frost & Sullivan’s evaluation focused on key areas of strategic effectiveness and execution. BioCatch demonstrates excellence by aligning its strategic initiatives with market demands, and by executing these strategies efficiently, consistently, and at scale—resulting in a distinct competitive advantage. “BioCatch’s behavioral biometric assets, targeted market approach, and customer collaboration are strategic advantages. Its deployment at more than 30 of the top 100 global banks shows the success of its strategy,” said Deepali Sathe, Senior Industry Analyst at Frost & Sullivan.

BioCatch’s long-term strategy is centered on fraud detection and prevention in the financial services sector. The company’s continuous investment in research and development, supported by customer feedback, has helped it address new security challenges and expand its presence in global markets.

Innovation is fundamental to BioCatch’s strategy, which is evident in the more than 90 patents it owns. The company’s fraud detection and prevention platform utilizes behavioral intelligence to effectively mitigate advanced forms of fraud such as social engineering scams, account takeover (ATO), mule accounts, and automated bot attacks.

“This recognition is a testament to our customers, who inspire us to continually push the boundaries of fraud prevention,” BioCatch Chief Strategy Officer Amelia Ahlgren said. “We are laser-focused on the financial services industry, where we deeply understand our customers’ challenges and partner with them to deliver innovation that makes banking safer every day. By aligning our strategy with their needs, we ensure our solutions drive measurable impact and lasting consumer trust.”

BioCatch demonstrates a strong dedication to customer success, which reinforces its leadership in the market. The company facilitates efficient implementation through a modular platform, offers flexible deployment solutions, and upholds exceptional service availability. Through direct engagement with leading global banks and a partner-led delivery model for the mid-market sector and direct engagement with leading global banks, BioCatch ensures scalable and effective value delivery across a broad range of market segments.

Frost & Sullivan commends BioCatch for setting a high standard in competitive strategy, execution, and market responsiveness. The company’s vision, innovation pipeline, and customer-first culture are shaping the future of fraud detection and prevention in the BFSI industry and driving tangible results at scale.

Each year, Frost & Sullivan presents the Competitive Strategy Leadership Recognition to a company that demonstrates outstanding strategy development and implementation, resulting in measurable improvements in market share, customer satisfaction, and competitive positioning. The recognition highlights forward-thinking organizations that are reshaping their industries through innovation and growth excellence.

Frost & Sullivan Best Practices Recognition
Frost & Sullivan’s Best Practices Recognitions honor companies across regional and global markets that exhibit exceptional achievement and consistent excellence in areas such as leadership, technological innovation, customer experience, and strategic product development. Each recognition is the result of a rigorous analytical process in which Frost & Sullivan industry experts benchmark performance through comprehensive interviews, deep-dive analysis, and extensive secondary research. The goal is to identify true best-in-class organizations that are driving transformative growth and setting new industry standards.

Contact us: Start the discussion.

Contact:
Ashley Shreve
E: ashley.weinkauf@frost.com 

About BioCatch
BioCatch prevents financial crime by recognizing patterns in human behavior, continuously collecting more than 3,000 anonymized data points – keystroke and mouse activity, touch screen behavior, physical device attributes, and more – as people interact with their digital banking platforms. With these inputs, BioCatch’s machine-learning models reveal patterns in user behavior and provide device intelligence that, together, distinguish the criminal from the legitimate. The company’s Customer Innovation Board – an industry-led initiative in partnership with American Express, Barclays, Citi Ventures, HSBC, National Australia Bank, and others – collaborates to pioneer innovative ways of leveraging customer relationships for improved fraud detection. Today, more than 30 of the world’s largest 100 banks and 287 total financial institutions deploy BioCatch solutions, analyzing 16 billion user sessions per month and protecting more than 532 million people on more than 1.6 billion devices around the world from fraud and financial crime.

Media/PR contact:
Mac King E: Mac.King@BioCatch.com

 

MAS9 Brings Digital Transformation to U.S. Martial Arts Schools With AI-Powered SaaS Platform

SEOUL, South Korea , Sept. 15, 2025 /PRNewswire/ — South Korean startup MAS9 has made a rapid entry into the U.S. Taekwondo market, onboarding more than 100 schools within a month of launching its paid SaaS platform. The company’s solution is the first business-to-business-to-consumer (B2B2C) digital management system designed specifically for martial arts schools in the United States.

The platform replaces manual administrative tasks—such as tuition collection, overdue payment reminders, and attendance tracking—with a fully automated system. Parents and students also benefit from real-time access to class schedules, training progress, and instructor feedback via MAS9’s dedicated mobile app and website.

Building on this momentum, MAS9 will introduce a one-click e-commerce feature in January 2026, giving school owners a new revenue opportunity. Without carrying inventory, owners will be able to launch online shops and sell uniforms, equipment, and merchandise directly to students and parents through the platform. The U.S. Taekwondo merchandise market is estimated at around $400 million, and MAS9’s upcoming feature is designed to help school operators capture this demand more effectively..

“MAS9 provides both operational efficiency and financial upside for school owners, which explains the strong adoption we’ve seen in such a short time,” said Dongho Ryoo, CEO of MAS9 USA. He added that the company has been able to accelerate adoption by rapidly incorporating feedback from U.S. school operators, leveraging more than two decades of local market experience.

Looking forward, MAS9 plans to integrate artificial intelligence into its system, with features such as student retention analytics, personalized training content, and financial forecasting tools.

Sang-Youb Lee, CEO of MAS9 said the company’s long-term ambition is to build a global Taekwondo business platform. “With 700,000 schools, 1.5 million instructors, and 80 million practitioners worldwide, Taekwondo represents a massive opportunity. Our early success in the U.S. validates our strategy and lays the groundwork for international expansion.”